Cervical Cancer Screening in Women With Systemic Lupus Erythematosus.
Journal
Arthritis care & research
ISSN: 2151-4658
Titre abrégé: Arthritis Care Res (Hoboken)
Pays: United States
ID NLM: 101518086
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
04
06
2020
accepted:
06
08
2020
pubmed:
18
8
2020
medline:
14
1
2022
entrez:
18
8
2020
Statut:
ppublish
Résumé
To determine rates of cervical cancer screening and associated abnormal results in women with systemic lupus erythematosus (SLE). We identified women with an initial diagnosis of SLE in the MarketScan Commercial Claims and Encounters Database from 2001 to 2014. Cervical cancer screening rates and associated diagnostic claims within 3 years of the initial claim were determined. Multivariable logistic regression was performed to evaluate the association of screening with lupus treatment. A matched logistic regression analysis was conducted to compare screening rates to those in age-matched women without connective tissue disease. We included 4,316 women with SLE. Screening rates were higher in women with SLE than in general controls (73.4% versus 58.5%; P < 0.001). Factors associated with decreased screening included recent time (odds ratio [OR] 0.70 [95% confidence interval (95% CI)] 0.55-0.89) (2012-2014 compared to 2001-2005), age ≥61 years (OR 0.27 [95% CI 0.18-0.39]), comorbidity score ≥2 (OR 0.71 [95% CI 0.6-0.83]), corticosteroid use (OR 0.77 [95% CI 0.61-0.97]), and use of immunosuppressants (OR 0.80 [95% CI 0.69-0.94]). Abnormal pathology result claims were more common in women with SLE than in general controls (12.3% versus 9.8%; P < 0.001). Though with higher rates than the general cohort, over 25% of the patients with SLE were not screened, and screening rates seem to be decreasing over time. Patients with SLE are at higher risk of abnormal cervical screening test results than controls, supporting the need for regular screening.
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1796-1803Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : Duncan Family Institute for Cancer Prevention and Risk Assessment
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2020, American College of Rheumatology.
Références
Mendoza-Pinto C, Garcia-Carrasco M, Vallejo-Ruiz V, Mendez-Martinez S, Taboada-Cole A, Etchegaray-Morales I, et al. Incidence of cervical human papillomavirus infection in systemic lupus erythematosus women. Lupus 2017;26:944-51.
Li TH, Lai CC, Wang WH, Chen WS, Tsao TP, Tsai CY, et al. Risk of severe herpes simplex virus infection in systemic lupus erythematosus: analysis of epidemiology and risk factors analysis in Taiwan. Ann Rheum Dis 2019;78:941-6.
Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term followup study in a Danish cohort. Arthritis Rheum 2011;63:3032-7.
Bernatsky S, Ramsey-Goldman R, Labrecque J, Joseph L, Boivin JF, Petri M, et al. Cancer risk in systemic lupus: an updated international multi-centre cohort study. J Autoimmun 2013;42:130-5.
Bae EH, Lim SY, Han KD, Jung JH, Choi HS, Kim CS, et al. Systemic lupus erythematosus is a risk factor for cancer: a nationwide population-based study in Korea. Lupus 2019;28:317-23.
Wang S, Chen Y, Xu X, Hu W, Shen H, Chen J. Prevalence of hepatitis B and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Oncotarget 2017;8:102437-45.
Rojo-Contreras W, Olivas-Flores EM, Gamez-Nava JI, Montoya-Fuentes H, Trujillo-Hernandez B, Trujillo X, et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis. Lupus 2012;21:365-72.
Tam LS, Chan AY, Chan PK, Chang AR, Li EK. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004;50:3619-25.
Wadstrom H, Arkema EV, Sjowall C, Askling J, Simard JF. Cervical neoplasia in systemic lupus erythematosus: a nationwide study. Rheumatology (Oxford) 2017;56:613-9.
Raposo A, Tani C, Costa J, Mosca M. Human papillomavirus infection and cervical lesions in rheumatic diseases: a systematic review. Acta Reumatol Port 2016;41:184-90.
Moscicki AB, Flowers L, Huchko MJ, Long ME, MacLaughlin KL, Murphy J, et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis 2019;23:87-101.
IBM Watson Health. IBM MarketScan Research Databases for Health Services Researchers (White Paper), 2019.
Watson M, Benard V, Flagg EW. Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003-2014. Prev Med Rep 2018;9:124-30.
Barnado A, Casey C, Carroll RJ, Wheless L, Denny JC, Crofford LJ. Developing electronic health record algorithms that accurately identify patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2017;69:687-93.
Hwang JP, Ahmed S, Ariza-Heredia EJ, Duan Z, Zhao H, Schmeler KM, et al. Low rate of cervical cancer screening among women with hematologic malignancies after stem cell transplant. Biol Blood Marrow Transplant 2018;24:1094-8.
Deyo R, Cherkin D, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;3:613-9.
Tani C, Carli L, Mosca M, Baldini C, Consensi A, Doveri M, et al. Adherence to cervical cancer screening in an Italian SLE cohort [in Italian]. Reumatismo 2011;63:11-7.
Hall IJ, Tangka FK, Sabatino SA, Thompson TD, Graubard BI, Breen N. Patterns and trends in cancer screening in the United States. Prev Chronic Dis 2018;15:E97.
Silver MI, Kobrin S. Exacerbating disparities?: Cervical cancer screening and HPV vaccination. Prev Med 2020;130:105902.
MacLaughlin KL, Jacobson RM, Breitkopf CR, Wilson PM, Jacobson DJ, Fan C, et al. Trends over time in pap and pap-HPV cotesting for cervical cancer screening. J Womens Health (Larchmt) 2019;28:244-9.
Tam LS, Chan PK, Ho SC, Yu MY, Yim SF, Cheung TH, et al. Risk factors for squamous intraepithelial lesions in systemic lupus erythematosus: a prospective cohort study. Arthritis Care Res (Hoboken) 2011;63:269-76.
Klumb EM, Araujo ML Jr, Jesus GR, Santos DB, Oliviera AV, Albuquerque EM, et al. Is higher prevalence of cervical intraepithelial neoplasia in women with lupus due to immunosuppression? J Clin Rheumatol 2010;16:153-7.
Nath R, Mant C, Luxton J, Hughes G, Raju KS, Shepherd P, et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum 2007;57:619-25.
Feldman CH, Liu J, Feldman S, Solomon DH, Kim SC. Risk of high-grade cervical dysplasia and cervical cancer in women with systemic lupus erythematosus receiving immunosuppressive drugs. Lupus 2017;26:682-9.
Kavosi H, Javinani A, Kazemi-Rahmatabadi Z, Alyasin A, Sefidbakht S, Gharibdoost F, et al. Cervical cancer screening and Pap test non-adherence risk factors in systemic sclerosis patients. Eur J Cancer Prev 2020;29:266-9.